Clinical Trial Update: Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia [Phase 3]

View source ↗

Summary

Phase 3 trial assessing whether flecainide reduces risk related to patent foramen ovale closure in patients with atrial arrhythmia or tachycardia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Arrhythmia
• Cryptogenic Stroke
• Patent Foramen Ovale

Drugs mentioned

• flecainide (flecainide)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Patent Foramen Ovale, Atrial Arrhythmia | Phase 3 | Status: ACTIVE_NOT_RECRUITING